The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy.
Anderson-Fabry disease is an X-linked recessive lysosomal storage disease resulting from deficient alpha-galactosidase A activity. The conception of the disease has changed within the last decade. Studies of the last years have shown that the disease is not limited to the classical full-blown manifestation in affected males, which is well known since more than a century, but may also occur in carrier females. The phenomenology may differ in severity and kind of organ manifestation. Cardiac and renal variants with solely disease manifestation of these organs have also been described in an increasing number. It is likely that a spectrum exists regarding alpha-galactosidase A activity in both genders on the one hand, and an additional one regarding the severity and the number of organs affected on the other. The purpose of this review is to sharpen physicians' perception of this disease. Early and accurate diagnosis is mandatory considering that this disorder is now, after introduction of the novel enzyme replacement therapy, a treatable disease.
Hauser
A C
AC
Department of Medicine III, Division of Nephrology and Dialysis, University of Vienna, Vienna, Austria. anna-christine.hauser@univie.ac.at
Lorenz
M
M
Sunder-Plassmann
G
G
D005128:Eye Diseases / Q000209:etiology; D000795:Fabry Disease / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use; D007674:Kidney Diseases / Q000209:etiology; D008297:Male; D010146:Pain / Q000209:etiology; D000519:alpha-Galactosidase / Q000627:therapeutic use
D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta